NUWIQ PUP Study

The largest prospective clinical trial of a single FVIII product in previously untreated patients with hemophilia A.

Review the NuProtect Study and Findings

News & stories

Check out our latest stories

Octapharma USA Grant Supports PANS/PANDAS Education Event at NHIA Conference March 27 in Washington, D.C.

Octapharma USA Research at AAAAI: cutaquig® Study at Higher Infusion Rates Presented

Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement

Octapharma Group delivers strong growth in sales and operating income in 2022

Patient engagement

Octapharma takes an active role in our community

We sponsor and support organizations worldwide.

Learn how we engage with patients

Our products

Products

Learn more about our products to treat rare diseases and other coagulopathies and bleeding disorders.